Intervention not reported
Adverse effects (related to the exercise programs) · People with hip or knee osteoarthritis
It is very uncertain whether the intervention changes adverse effects (related to the exercise programs) (very low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events or withdrawals (due to adverse events) ‐ not reported · People with hip or knee osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain ‐ duration exercise WOMAC (VAS or Likert) from 0 to 20 · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Pain ‐ resistance exercise WOMAC (VAS or Likert) from 0 to 20 · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Function ‐ duration exercise WOMAC from 0 to 68 · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Function ‐ resistance exercise WOMAC from 0 to 68 · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring a course of OCSa 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
AQLQ score (Scale 1 to 7, where 1 = severely impaired and 7 = no impairment) · adults with asthma
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
SAEs · adults with asthma
ICS + LAMA add‐on showed no clear difference in SAEs (all cause) compared with ICS dose increase (low certainty).
1 finding from 1 review
Exacerbations needing hospitalisation · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring hospitalisation 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
Exacerbations leading to ED visits · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring ED visit 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
FEV1 · adults with asthma
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate
ACQ score Scale = 0 to 6 (0 = no impairment; 6 = maximum impairment) · adults with asthma
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Intervention not reported
Incidence of pulmonary tuberculosis in children with HIV infection ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of pulmonary tuberculosis in children with HIV infection ‐… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mean FEV1 % predicted ‐ azithromycin prophylaxis only · children with cystic fibrosis aged 12 years and under
1 finding from 1 review
Intervention not reported
Mean FEV1 % predicted ‐ ciprofloxacin prophylaxis only · children with cystic fibrosis aged 12 years and under
1 finding from 1 review
Intervention not reported
Episodes of pulmonary exacerbations ‐ azithromycin prophylaxis only · children with cystic fibrosis aged 12 years and under
The intervention leads to lower episodes of pulmonary exacerbations ‐ azithromycin prophylaxis only (high certainty).
1 finding from 1 review
Intervention not reported
Incidence of Pneumocystis carinii pneumonia infection in children with cancer ‐ trimethoprim‐sulfamethoxazole prophylaxis only · children with cancers aged 12 years and under
The intervention probably leads to lower incidence of Pneumocystis carinii pneumonia infection in children… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ overall · children with HIV infection aged 12 years and under
The intervention showed no clear difference in mortality in children with HIV infection ‐ overall (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ co‐trimoxazole prophylaxis only · children with HIV infection aged 12 years and under
The intervention probably leads to lower mortality in children with HIV infection ‐ co‐trimoxazole… (moderate certainty).
1 finding from 1 review